Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
97.967,45
-0,72%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biogen Inc (BIIB) Biogen Inc (BIIB) Notizie

BIIB

Biogen (BIIB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIIB
DataOraFonteTitoloSimboloCompagnia
09/12/202422:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
09/12/202416:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
05/12/202400:31PR Newswire (US)"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in MexicoNASDAQ:BIIBBiogen Inc
28/11/202401:31PR Newswire (US)"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNASDAQ:BIIBBiogen Inc
19/11/202407:00GlobeNewswire Inc.Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease ActivityNASDAQ:BIIBBiogen Inc
14/11/202419:29PR Newswire (US)Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's DiseaseNASDAQ:BIIBBiogen Inc
14/11/202417:23GlobeNewswire Inc.Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
31/10/202400:30GlobeNewswire Inc.Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) ConferenceNASDAQ:BIIBBiogen Inc
30/10/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
30/10/202421:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
30/10/202411:37IH Market NewsUS Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge UpNASDAQ:BIIBBiogen Inc
29/10/202423:00GlobeNewswire Inc.Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological DiseasesNASDAQ:BIIBBiogen Inc
29/10/202413:00GlobeNewswire Inc.Biogen Appoints Daniel Quirk, MD, as Chief Medical OfficerNASDAQ:BIIBBiogen Inc
28/10/202413:30GlobeNewswire Inc.Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025NASDAQ:BIIBBiogen Inc
27/10/202402:15GlobeNewswire Inc.Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
24/10/202413:30GlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual ConferenceNASDAQ:BIIBBiogen Inc
22/10/202413:30GlobeNewswire Inc.Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:BIIBBiogen Inc
09/10/202413:30GlobeNewswire Inc.Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant RecipientsNASDAQ:BIIBBiogen Inc
08/10/202413:30GlobeNewswire Inc.New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMANASDAQ:BIIBBiogen Inc
08/10/202401:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
24/09/202407:00GlobeNewswire Inc.UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024NASDAQ:BIIBBiogen Inc
12/09/202413:30GlobeNewswire Inc.Biogen Board Appoints Two New Independent DirectorsNASDAQ:BIIBBiogen Inc
04/09/202413:30GlobeNewswire Inc.Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMANASDAQ:BIIBBiogen Inc
22/08/202411:10PR Newswire (US)Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great BritainNASDAQ:BIIBBiogen Inc
17/08/202400:40Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BIIBBiogen Inc
31/07/202415:00PR Newswire (US)Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersenNASDAQ:BIIBBiogen Inc
30/07/202423:15GlobeNewswire Inc.New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAICNASDAQ:BIIBBiogen Inc
30/07/202423:00PR Newswire (US)New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20NASDAQ:BIIBBiogen Inc
30/07/202413:30GlobeNewswire Inc.Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
26/07/202413:20GlobeNewswire Inc.Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European UnionNASDAQ:BIIBBiogen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIIB

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
CPR
Davide Campari
BIT
AMP
Amplifon
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network